Dr. Jim Tartaglia currently holds the position of Vice President, Global Project Function Head for Sanofi Pasteur and is based in Swiftwater, PA, USA. Prior to this role, Jim held positions of site head for Research, site head for R&D at the Toronto site, and global head of Program/Project Leader Function.
Prior to joining Sanofi Pasteur-Canada in 1999, Jim held the position of Executive Director of Research at Virogenetics Corporation of Troy, New York, a former subsidiary of sanofi pasteur. While at Virogenetics, he helped develop the poxvirus vector technology as an immunization vehicle for both veterinary and human application.
Prior to joining Virogenetics in 1990, Jim worked as a Research Scientist with the New York State Department of Health and a Post-doctoral Fellow at Roche Institute of Molecular Biology in Nutley, New Jersey. He holds a Ph.D. from the Department of Microbiology and Immunology at the Albany Medical College and a B.S. in Biology from Bucknell University in Lewisburg, Pa.
Dr. Tartaglia is an inventor on over 20 patents relating to recombinant vaccines and has authored over 130 publications in the areas of molecular virology and recombinant vaccine technology.
Dr. Tartaglia has been involved in the licensure of several vaccines in the human and veterinary fields and was a key figure in the HIV Thai trial, RV144, which led to first demonstration that a vaccine regimen can reduce the risk of acquisition to HIV infection.
Dr. Tartaglia participates as associate editor/reviewer for certain peer-reviewed journals, as well as serves as expert contributor to Faculty of 1000.